Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the ...

Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – ...

Northern Trust Corp (NTRS) is expected to report $2.05 for 2Q. Otis Worldwide Corp (OTIS) is expected to report $0.93 for 2Q. PROG Holdings Inc (PRG) is expected to report $0.74 for 2Q. Pacific ...

Dow, Nasdaq, S&P 500 opened flat on Tuesday's US market session as investors focused on US President Donald Trump's trade ...

Replimune stock was down 76.88% in pre-market trading on Tuesday, following a 1.94% rally yesterday. The company’s shares ...

Fintel reports that on July 22, 2025, Wedbush downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Neutral. Analyst Price Forecast Suggests 725.97% Upside As of July 17, ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. ("Replimune or the "Company") (NASDAQ: REPL).

Replimune's RP1 treatment for advanced melanoma faces FDA rejection due to trial design issues, despite promising results ...

"REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% After FDA Response Letter -- BFA Law Announces Securities Fraud Investigation And Urges Investors To Contact The Firm >REPL" was published ...

Replimune stock (ticker: REPL) cratered on Tuesday after the biotech said the U.S. Food and Drug Administration rejected an ...

The FDA has issued a complete response letter to Replimune indicating it is unable to approve the biologics license ...

Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why ...